News India India's top genome scientists recommend booster dose for those above 40

India's top genome scientists recommend booster dose for those above 40

The recommendation came amid demands for a booster dose of covid vaccines by lawmakers during a discussion in the Lok Sabha on the pandemic situation in the country.  

Top Indian genome scientists have recommended a booster dose of COVID-19 vaccines for those above 40 years in the weekly bulletin of the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG). Image Source : PTI FILE IMAGETop Indian genome scientists have recommended a booster dose of COVID-19 vaccines for those above 40 years in the weekly bulletin of the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG).

Top Indian genome scientists have recommended a booster dose of COVID-19 vaccines for those above 40 years with preference to high-risk and high-exposure population.

The recommendation was made in the weekly bulletin of the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of COVID-19.

"Vaccination of all remaining unvaccinated at-risk people and consideration of a booster dose for those 40 years of age and over, first targeting the most high-risk / high-exposure may be considered," the INSACOG bulletin said.

The recommendation came amid demands for a booster dose of covid vaccines by lawmakers during a discussion in the Lok Sabha on the pandemic situation in the country.

The INSACOG said genomic surveillance will be critical for early detection of the presence of this variant, to enable necessary public health measures.

It also recommended monitoring travel to and from the known affected areas, and contact tracing of COVID-19 cases with an epidemiological link to the affected areas has been implemented along with increased testing.

"Vaccination of all remaining unvaccinated at-risk people and consideration of a booster dose for those 40 years of age and over, first targeting the most high-risk / high-exposure may be considered since low levels of neutralising antibodies from current vaccines are unlikely to be sufficient to neutralise Omicron, although the risk of severe disease is still likely to be reduced," it said.

Also Read | Booster dose of six Covid vaccines safe, increases immunity: Lancet study

 

Latest India News